Drug intelligence / Profile preview

INVIVO-mAb Bi-Specific

Development stage: Preclinical
Lead developer: SET Technology
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies
Administration: Parenteral

Overview

INVIVO-mAb Bi-Specific is a DNA-encoded, in vivo-expressed bispecific monoclonal antibody being developed by SET Technology. The program utilizes SET Technology's proprietary platform to deliver DNA sequences that instruct the patient's own cells to produce bispecific antibodies directly within the body. This approach aims to overcome the manufacturing and stability challenges associated with traditional recombinant bispecific antibodies. The lead application for this program is in veterinary oncology, where it is currently in the research and preclinical stages of development.

Other names: INVIVO-mAb Bispecific

Beyond the preview

Go deeper on INVIVO-mAb Bi-Specific.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INVIVO-mAb Bi-Specific.

Explore the full profile